Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02204813 · ClinicalTrials.gov registry record · Phase 1
To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT02204813 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 13 participants.
The verdict
NCT02204813, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
There is a marked and long-lasting improvement in glucose homeostasis that follows Roux-en-y gastric bypass surgery (RYGB) in humans. This improvement has been attributed in large part to an intestinal hormone, called GLP-1, that is released into the circulation immediately after eating. The purpose of this study is to determine if GLP-1 mediates the beneficial effects of RYGB surgery on glucose homeostasis in humans.
Interventions
- DRUG Placebo
- DRUG Lo-Xenin
- DRUG Hi-Xenin
- DRUG Extra Hi-Xenin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-11-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02204813
The ClinicalTrials.gov registry entry for NCT02204813 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02204813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02204813 about?
NCT02204813 is a clinical study titled "To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery". There is a marked and long-lasting improvement in glucose homeostasis that follows Roux-en-y gastric bypass surgery (RYGB) in humans. This improvement has been attributed in large part to an intestinal hormone, called GLP-1, that is released into the circulation immediately after eating. The purpose...
What is the current status of trial NCT02204813?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2014-07. Estimated completion is 2015-11-17.
What interventions are being tested in trial NCT02204813?
The interventions under investigation include: Placebo (DRUG), Lo-Xenin (DRUG), Hi-Xenin (DRUG), Extra Hi-Xenin (DRUG).
Who is sponsoring clinical trial NCT02204813?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.